2 products of ‘Amosartan,’ Hanmi’s modified medicines,’ record highest annual manufacturing performance with KRW 57.5 billion
There were 9 products making more than KRW 10 billion last year out of pharmaceutical products approved as incrementally modified drug, and 2 products of Amosartan, Hanmi Pharm’s antihypertensives, recorded the highest with KRW 57.5 billion in production.
According to the Ministry of Food and Dr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
